Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Poor-quality medicines are a major problem for health-care systems in resource-poor settings as identifying falsified medicines requires a complex laboratory infrastructure such as a Medicines Quality Control Laboratory. We report here an evaluation of a low-cost, handheld near-infrared spectrometer (NIRS) device by analyzing a library of artemisinin-based combination therapy (ACT) medicines to determine its usefulness as a drug-screening tool. The “SCiO” research prototype device was used to collect NIR spectra of a library of ACT and artesunate monotherapy medicine samples previously collected in Bioko Island and Equatorial Guinea and Kintampo, Ghana. The quality of these samples had been categorized as falsified, substandard, and quality assured based on the amount of stated active pharmaceutical ingredients detected using high-performance liquid chromatography photodiode array. Numerical analyses were performed on the NIR spectra to assess the usefulness of NIR to identify falsified and substandard medicines. The NIRS device was successful at detecting falsified medicines in all cases where the library contained both quality assured and falsified medicines of the same stated brand of medicines. The NIRS device was successful at identifying substandard amounts of artesunate but not amodiaquine in the ACT samples ( = 15) of artesunate–amodiaquine. This work reveals that this low-cost, portable NIRS device is promising for screening ACTs for falsified samples and could enable widespread drug screening at all points of the health system.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Kaur H, Clarke S, Lalani M, Phanouvong S, Guérin P, McLoughlin A, Wilson BK, Deats M, Plançon A, Hopkins H, Miranda D, Schellenberg D, , 2016. Fake anti-malarials: start with the facts. Malar J 15: 86.[Crossref] [Google Scholar]
  2. Nayyar GML, Breman JG, Newton PN, Herrington J, , 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488496.[Crossref] [Google Scholar]
  3. World Health Organization, 2011. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa. Geneva, Switzerland: World Health Organization, 1118. [Google Scholar]
  4. Gautam CS, Utreja A, Singal GL, , 2009. Spurious and counterfeit drugs: a growing industry in the developing world. Postgrad Med J 85: 251256.[Crossref] [Google Scholar]
  5. Attaran A, Berry D, Basheer S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M, , 2012. How to achieve international action on falsified and substandard medicines. BMJ 7381: 16. [Google Scholar]
  6. World Health Organization, 2011. Counterfeit, FAQs. Available at: http://www.who.int/medicines/services/counterfeit/faqs/QandAsUpdateJuly11.pdf. Accessed September 29, 2016. [Google Scholar]
  7. ACT Consortium, 2016. Analysing the Quality and Authenticity of ACT Drugs. Available at: http://www.actconsortium.org/projects/9/analysing-the-quality-and-authenticity-of-act-drugs. Accessed September 29, 2016. [Google Scholar]
  8. Hall Z, Allan EL, van Schalkwyk DA, van Wyk A, Kaur H, , 2016. Degradation of artemisinin-based combination therapies under tropical conditions. Am J Trop Med Hyg 94: 9931001.[Crossref] [Google Scholar]
  9. 2013. Global ACT Supply Chain Threats Conference. Available at: http://www.theglobalfund.org/en/sourcing/updates/2013-07-09_Innovation_and_Global_ACT_Supply_Chain_Threats_Conference/#. Accessed September 27, 2016. [Google Scholar]
  10. Martino R, Gilard V, , 2010. Counterfeit drugs: analytical techniques for their identification. Anal Bioanal Chem 398: 7792.[Crossref] [Google Scholar]
  11. Markert H, Ring J, Campbell N, , 2011. A comparison of four commercially available portable Raman spectrometers. National Forensic Science Technology Center 727: 18. [Google Scholar]
  12. Hajjou M, Qin Y, Bradby S, Bempong D, Lukulay P, , 2013. Assessment of the performance of a handheld Raman device for potential use as a screening tool in evaluating medicines quality. J Pharm Biomed Anal 74: 4755.[Crossref] [Google Scholar]
  13. Ricci C, Nyadong L, Yang F, Fernandez FM, Brown CD, Newton PN, Kazarian SG, , 2008. Assessment of hand-held Raman instrumentation for in situ screening for potentially counterfeit artesunate antimalarial tablets by FT-Raman spectroscopy and direct ionization mass spectrometry. Anal Chim Acta 3: 178186.[Crossref] [Google Scholar]
  14. Bate R, Tren R, Hess K, Mooney L, Porter K, , 2009. Pilot study comparing technologies to test for substandard drugs in field Settings. Afr J Pharm 3: 165170. [Google Scholar]
  15. Ranieri N, Tabernero P, Green MD, Verbois L, Herrington J, Sampson E, Satzger RD, Phonlavong C, Thao K, Newton PN, Witkowski MR, , 2014. Evaluation of a new handheld instrument for the detection of counterfeit artesunate by visual fluorescence comparison. Am J Trop Med Hyg 91: 920924.[Crossref] [Google Scholar]
  16. Tivura M, Asante I, van Wyk A, Gyaase S, Malik N, Mahama E, Hostetler DM, Fernandez FM, Asante KP, Kaur H, Owusu-Agyei S, , 2016. Quality of artemisinin-based combination therapy for malaria found in Ghanaian markets and public health implications of their use. BMC Pharmacol Toxicol 17: 48.[Crossref] [Google Scholar]
  17. Kauss T, Fawaz F, Guyot M, Lagueny AM, Dos Santos I, Bonini F, Olliaro P, Caminiti A, Millet P, , 2010. Fixed artesunate–amodiaquine combined pre-formulation study for the treatment of malaria. Int J Pharm 395: 198204.[Crossref] [Google Scholar]
  18. Lacaze C, Kauss T, Kiechel JR, Caminiti A, Fawaz F, Terrassin L, Cuart S, Grislain L, Navaratnam V, Ghezzoul B, Gaudin K, White NJ, Olliaro PL, Millet P, , 2011. The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership. Malar J 10: 142.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 15 Nov 2016
  • Accepted : 04 Jan 2017
  • Published online : 20 Feb 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error